SCHEMBL1033458

SCHEMBL1033458

CC1CCC(Nc2ncc(-c3ccc(OCC(F)(F)F)cc3)cn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
GRM5 P41594 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
ULK1 O75385 1/20 0.39
SCN5A Q14524 1/20 0.38
HDAC6 Q9UBN7 2/20 0.38
SCN9A Q15858 1/20 0.38
FLT3 P36888 3/20 0.37
KIT P10721 1/20 0.37
CACNA1G O43497 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNA1I Q9P0X4 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
GABBR2 O75899 1/20 0.36
GABBR1 Q9UBS5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033459 1.00 PTGS1 (0.41) PTGS1PTGS2GRM5IRAK4ALDH1A1
SCHEMBL1333238 0.86 GABBR2 (0.49) GRM5IRAK4SCN5ASCN9AGABBR2
SCHEMBL12127078 0.86 GABBR2 (0.49) GRM5IRAK4SCN5ASCN9AGABBR2
SCHEMBL1333239 0.86 GABBR2 (0.49) GRM5IRAK4SCN5ASCN9AGABBR2
SCHEMBL1334512 0.84 GABBR2 (0.46) GRM5IRAK4ULK1FLT3KIT
SCHEMBL1334511 0.84 GABBR2 (0.46) GRM5IRAK4ULK1FLT3KIT
SCHEMBL1032441 0.84 HPGD (0.41) GRM5IRAK4ALDH1A1
SCHEMBL1032440 0.84 HPGD (0.41) GRM5IRAK4ALDH1A1
SCHEMBL1032533 0.83 MAPK6 (0.47) GRM5IRAK4
SCHEMBL1032531 0.83 MAPK6 (0.47) GRM5IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010068863-A2 PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS PTGS1 729/4885PTGS2 860/4885GRM5 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.